Network meta-analysis
Percent body weight change
Overweight or obesity without diabetes (adults)
weeks 40 to 104 (target week 68)Not stated by the trialsEach dose separatelyMean differenceSeparate part 2 of a disconnected network
17
Randomized trials
14
Treatments
8,032
Participants
42
Trial arms
In plain language
Across 17 trials with 8,032 participants, 11 of 13 treatments had a clearly better result than placebo on percent body weight change, and for 2 the evidence could not tell them apart from placebo. The most favorable estimate was for Semaglutide 1.0 mg subcutaneous once weekly: mean difference -14.57 percentage points (95% credible interval -19.73 to -8.93).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Mean difference in percentage points. Lower values favor the treatment.
| Treatment | Bayesian MD (95% CrI) | 95% prediction interval | Frequentist MD (95% CI) | Verdict |
|---|---|---|---|---|
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | -14.57 (-19.73 to -8.93) | -20.55 to -8.04 | -14.80 (-18.74 to -10.86) | Better |
| Semaglutide 50 mg oral once daily (higher dose oral program) SEMA_PO_50MG_QD | -13.47 (-17.07 to -9.72) | -18.41 to -8.45 | -13.60 (-16.22 to -10.98) | Better |
| Semaglutide 0.4 mg injection once daily SEMA_SC_0p4MG_QD | -12.57 (-15.91 to -9.09) | -17.18 to -7.77 | -12.77 (-15.32 to -10.23) | Better |
| Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW | -12.10 (-13.88 to -10.75) | -15.97 to -8.50 | -12.04 (-13.24 to -10.84) | Better |
| Semaglutide 0.2 mg injection once daily SEMA_SC_0p2MG_QD | -9.13 (-12.57 to -5.45) | -13.93 to -4.19 | -9.31 (-12.12 to -6.50) | Better |
| Semaglutide 0.3 mg injection once daily SEMA_SC_0p3MG_QD | -8.82 (-12.02 to -5.32) | -13.45 to -3.93 | -8.98 (-11.53 to -6.43) | Better |
| Semaglutide 1.7 mg injection once weekly SEMA_SC_1p7MG_QW | -8.24 (-11.62 to -4.87) | -13.00 to -3.58 | -8.27 (-10.93 to -5.60) | Better |
| Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW | -7.89 (-12.80 to -3.02) | -13.70 to -2.12 | -8.10 (-12.33 to -3.86) | Better |
| Semaglutide 0.1 mg injection once daily SEMA_SC_0p1MG_QD | -6.17 (-9.59 to -2.57) | -10.95 to -1.19 | -6.33 (-9.13 to -3.53) | Better |
| Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW | -6.17 (-10.38 to -1.91) | -11.52 to -0.86 | -6.27 (-9.89 to -2.64) | Better |
| Liraglutide 3.0 mg subcutaneous once daily LIRA_SC_3p0MG_QD | -5.44 (-6.89 to -4.01) | -9.09 to -1.68 | -5.46 (-6.56 to -4.37) | Better |
| Semaglutide 0.05 mg injection once daily SEMA_SC_0p05MG_QD | -3.56 (-7.06 to 0.01) | -8.30 to 1.49 | -3.70 (-6.51 to -0.89) | Unclear |
| Standard care or no added treatment STANDARD_CARE | 0.07 (-3.80 to 4.17) | -5.00 to 5.37 | -0.06 (-3.06 to 2.93) | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | SEMA_SC_1p0MG_QW | SEMA_PO_50MG_QD | SEMA_SC_0p4MG_QD | SEMA_SC_2p4MG_QW | SEMA_SC_0p2MG_QD | SEMA_SC_0p3MG_QD | SEMA_SC_1p7MG_QW | TIRZ_SC_15MG_QW | SEMA_SC_0p1MG_QD | TIRZ_SC_10MG_QW | LIRA_SC_3p0MG_QD | SEMA_SC_0p05MG_QD | STANDARD_CARE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 14.57 8.93 to 19.73 | 13.47 9.72 to 17.07 | 12.57 9.09 to 15.91 | 12.10 10.75 to 13.88 | 9.13 5.45 to 12.57 | 8.82 5.32 to 12.02 | 8.24 4.87 to 11.62 | 7.89 3.02 to 12.80 | 6.17 2.57 to 9.59 | 6.17 1.91 to 10.38 | 5.44 4.01 to 6.89 | 3.56 -0.01 to 7.06 | -0.07 -4.17 to 3.80 |
| SEMA_SC_1p0MG_QW | -14.57 -19.73 to -8.93 | SEMA_SC_1p0MG_QW | -1.07 -7.23 to 5.41 | -1.98 -8.18 to 4.32 | -2.48 -7.66 to 3.58 | -5.43 -11.85 to 1.10 | -5.75 -11.76 to 0.44 | -6.32 -12.45 to 0.21 | -6.68 -13.63 to 0.70 | -8.41 -14.59 to -2.00 | -8.43 -15.20 to -1.51 | -9.13 -14.17 to -3.62 | -10.99 -16.99 to -4.63 | -14.60 -18.19 to -10.93 |
| SEMA_PO_50MG_QD | -13.47 -17.07 to -9.72 | 1.07 -5.41 to 7.23 | SEMA_PO_50MG_QD | -0.90 -5.92 to 3.98 | -1.38 -5.13 to 2.96 | -4.32 -9.45 to 0.79 | -4.69 -9.52 to 0.14 | -5.22 -10.10 to -0.19 | -5.55 -11.67 to 0.56 | -7.34 -12.41 to -2.28 | -7.34 -12.89 to -1.58 | -8.04 -11.85 to -4.01 | -9.91 -14.84 to -4.84 | -13.53 -18.87 to -8.29 |
| SEMA_SC_0p4MG_QD | -12.57 -15.91 to -9.09 | 1.98 -4.32 to 8.18 | 0.90 -3.98 to 5.92 | SEMA_SC_0p4MG_QD | -0.49 -4.00 to 3.55 | -3.46 -7.37 to 0.44 | -3.77 -7.51 to -0.20 | -4.32 -9.04 to 0.47 | -4.66 -10.71 to 1.34 | -6.45 -10.29 to -2.44 | -6.44 -11.86 to -0.91 | -7.16 -10.40 to -3.68 | -9.02 -12.86 to -5.09 | -12.63 -17.81 to -7.54 |
| SEMA_SC_2p4MG_QW | -12.10 -13.88 to -10.75 | 2.48 -3.58 to 7.66 | 1.38 -2.96 to 5.13 | 0.49 -3.55 to 4.00 | SEMA_SC_2p4MG_QW | -2.99 -7.09 to 0.66 | -3.27 -7.29 to 0.07 | -3.84 -7.48 to -0.65 | -4.26 -9.52 to 0.82 | -5.94 -10.06 to -2.32 | -5.95 -10.61 to -1.54 | -6.65 -8.87 to -4.85 | -8.52 -12.54 to -4.98 | -12.14 -16.81 to -8.24 |
| SEMA_SC_0p2MG_QD | -9.13 -12.57 to -5.45 | 5.43 -1.10 to 11.85 | 4.32 -0.79 to 9.45 | 3.46 -0.44 to 7.37 | 2.99 -0.66 to 7.09 | SEMA_SC_0p2MG_QD | -0.33 -4.19 to 3.55 | -0.92 -5.75 to 4.18 | -1.25 -7.20 to 5.04 | -2.98 -7.01 to 1.23 | -2.96 -8.44 to 2.60 | -3.71 -7.17 to -0.01 | -5.61 -9.62 to -1.55 | -9.21 -14.37 to -4.00 |
| SEMA_SC_0p3MG_QD | -8.82 -12.02 to -5.32 | 5.75 -0.44 to 11.76 | 4.69 -0.14 to 9.52 | 3.77 0.20 to 7.51 | 3.27 -0.07 to 7.29 | 0.33 -3.55 to 4.19 | SEMA_SC_0p3MG_QD | -0.56 -5.19 to 4.38 | -0.89 -6.86 to 5.02 | -2.64 -6.57 to 1.30 | -2.63 -7.99 to 2.92 | -3.36 -6.57 to 0.05 | -5.23 -9.06 to -1.46 | -8.86 -13.82 to -4.06 |
| SEMA_SC_1p7MG_QW | -8.24 -11.62 to -4.87 | 6.32 -0.21 to 12.45 | 5.22 0.19 to 10.10 | 4.32 -0.47 to 9.04 | 3.84 0.65 to 7.48 | 0.92 -4.18 to 5.75 | 0.56 -4.38 to 5.19 | SEMA_SC_1p7MG_QW | -0.39 -6.22 to 5.49 | -2.09 -7.06 to 2.70 | -2.09 -7.44 to 3.31 | -2.82 -6.37 to 0.88 | -4.67 -9.72 to 0.15 | -8.28 -13.64 to -3.19 |
| TIRZ_SC_15MG_QW | -7.89 -12.80 to -3.02 | 6.68 -0.70 to 13.63 | 5.55 -0.56 to 11.67 | 4.66 -1.34 to 10.71 | 4.26 -0.82 to 9.52 | 1.25 -5.04 to 7.20 | 0.89 -5.02 to 6.86 | 0.39 -5.49 to 6.22 | TIRZ_SC_15MG_QW | -1.76 -7.79 to 4.43 | -1.75 -6.44 to 3.07 | -2.44 -7.54 to 2.55 | -4.31 -10.38 to 1.74 | -7.95 -14.22 to -1.61 |
| SEMA_SC_0p1MG_QD | -6.17 -9.59 to -2.57 | 8.41 2.00 to 14.59 | 7.34 2.28 to 12.41 | 6.45 2.44 to 10.29 | 5.94 2.32 to 10.06 | 2.98 -1.23 to 7.01 | 2.64 -1.30 to 6.57 | 2.09 -2.70 to 7.06 | 1.76 -4.43 to 7.79 | SEMA_SC_0p1MG_QD | -0.01 -5.63 to 5.56 | -0.73 -4.22 to 2.92 | -2.58 -6.67 to 1.43 | -6.25 -11.40 to -1.09 |
| TIRZ_SC_10MG_QW | -6.17 -10.38 to -1.91 | 8.43 1.51 to 15.20 | 7.34 1.58 to 12.89 | 6.44 0.91 to 11.86 | 5.95 1.54 to 10.61 | 2.96 -2.60 to 8.44 | 2.63 -2.92 to 7.99 | 2.09 -3.31 to 7.44 | 1.75 -3.07 to 6.44 | 0.01 -5.56 to 5.63 | TIRZ_SC_10MG_QW | -0.69 -5.13 to 3.78 | -2.64 -8.04 to 2.97 | -6.18 -12.16 to -0.47 |
| LIRA_SC_3p0MG_QD | -5.44 -6.89 to -4.01 | 9.13 3.62 to 14.17 | 8.04 4.01 to 11.85 | 7.16 3.68 to 10.40 | 6.65 4.85 to 8.87 | 3.71 0.01 to 7.17 | 3.36 -0.05 to 6.57 | 2.82 -0.88 to 6.37 | 2.44 -2.55 to 7.54 | 0.73 -2.92 to 4.22 | 0.69 -3.78 to 5.13 | LIRA_SC_3p0MG_QD | -1.88 -5.48 to 1.62 | -5.49 -9.41 to -1.91 |
| SEMA_SC_0p05MG_QD | -3.56 -7.06 to 0.01 | 10.99 4.63 to 16.99 | 9.91 4.84 to 14.84 | 9.02 5.09 to 12.86 | 8.52 4.98 to 12.54 | 5.61 1.55 to 9.62 | 5.23 1.46 to 9.06 | 4.67 -0.15 to 9.72 | 4.31 -1.74 to 10.38 | 2.58 -1.43 to 6.67 | 2.64 -2.97 to 8.04 | 1.88 -1.62 to 5.48 | SEMA_SC_0p05MG_QD | -3.63 -8.78 to 1.37 |
| STANDARD_CARE | 0.07 -3.80 to 4.17 | 14.60 10.93 to 18.19 | 13.53 8.29 to 18.87 | 12.63 7.54 to 17.81 | 12.14 8.24 to 16.81 | 9.21 4.00 to 14.37 | 8.86 4.06 to 13.82 | 8.28 3.19 to 13.64 | 7.95 1.61 to 14.22 | 6.25 1.09 to 11.40 | 6.18 0.47 to 12.16 | 5.49 1.91 to 9.41 | 3.63 -1.37 to 8.78 | STANDARD_CARE |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 11 of 17 | Type 2 diabetes share in weight trials (percent of participants) effect modifier; 17 of 17 | Sex (percent female) effect modifier, prognostic factor; 17 of 17 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 13 of 17 | Treatment duration (weeks) effect modifier; 17 of 17 | Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 17 of 17 |
|---|---|---|---|---|---|---|
| STEP 5 S000214 | 38.55 | 0 population codes | 77.6 | 0.65 | 104 | standard |
| S-LITE S000371 | 32.62 | 0 population codes | 64.51 | not reported | 52 | intensive |
| BARI-STEP S000434 | 41.5 | 10 | 82.85 | 2.85 | 68 | standard |
| NCT01272219 S000492 | 38.3 | 0 population codes | 78.5 | not reported | 56 | standard |
| STEP 10 S000832 | 39.9 | 0 population codes | 71.01 | 4.35 | 52 | not_reported |
| NCT03038620 S000866 | 37.65 | 0 population codes | 92.25 | 0 | 40 | standard |
| SURMOUNT-CN S001086 | body weight 91.8 kg | 0 population codes | 49.05 | 100 | 52 | standard |
| NCT00781937 S001278 | 35.6 | 0 population codes | 81.28 | 0.24 | 56 | standard |
| STEP7 S001288 | not reported | 0 population codes | 45.33 | 90.67 | 44 | standard |
| STABLE Wt Loss S001294 | 37.48 | 0 population codes | 78.36 | 4.2 | 60 | not_reported;standard |
| OASIS 1 S001472 | not reported | 0 population codes | 72.71 | 10.79 | 68 | not_reported |
| STEP 8 S001600 | not reported | 0 population codes | 78.4 | 3.85 | 68 | standard |
| STRIVE S001687 | 45.96 | 35.5 | 64.28 | 3.56 | 104 | intensive |
| STEP 6 S002102 | not reported | 0 population codes | 36.91 | 100 | 68 | not_reported |
| NCT02453711 S002317 | body weight 111.5 kg | 0 population codes | 64.68 | 0.94 | 52 | standard |
| S003017 S003017 | 38.05 | 0 population codes | 87.5 | not reported | 52.14 | standard |
| S003032 S003032 | 39.06 | 0 population codes | 67.5 | not reported | 34.76 | intensive |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Baseline BMI or body weight: not reported by 6 of 17 trials
- FlagBaseline, Baseline BMI or body weight: design means range from 36.4 (LIRA_SC_3p0MG_QD vs PLACEBO) to 46.0 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) kg/m2; threshold 3
- FlagBaseline, Type 2 diabetes share in weight trials: design means range from 0.0 (LIRA_SC_3p0MG_QD vs PLACEBO) to 35.5 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) percent of participants; threshold 20
- FlagBaseline, Sex: design means range from 36.9 (PLACEBO vs SEMA_SC_1p7MG_QW vs SEMA_SC_2p4MG_QW) to 80.8 (LIRA_SC_3p0MG_QD vs PLACEBO) percent female; threshold 15
- FlagBaseline, Asian ancestry or region: not reported by 4 of 17 trials
- FlagBaseline, Asian ancestry or region: design means range from 0.1 (LIRA_SC_3p0MG_QD vs PLACEBO) to 100.0 (PLACEBO vs SEMA_SC_1p7MG_QW vs SEMA_SC_2p4MG_QW) percent Asian; threshold 30
- FlagBaseline, Treatment duration: design means range from 34.8 (SEMA_SC_1p0MG_QW vs STANDARD_CARE) to 104.0 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) weeks; threshold 26
- NoteOutcome assessment, time point: selected time points span 40 to 78 weeks
- NoteOutcome assessment, analysis set: mixed: completers 4, full_analysis 9, modified_itt 1, per_protocol 1, randomized 2
- NoteOutcome assessment, definition: mixed: not stated 13, percent change in body weight 1, percent change in body weight from baseline 1, percent change in body weight from randomization after the diet to end of treatment 1, percent change in fasting weight from randomization 1
- NoteRisk of bias, blinding: mixed: double_blind 15, open_label 2
- NoteRisk of bias, funding: mixed: industry 14, mixed 2, non_industry 1
- NoteData handling, input conversions: arms_combined 4, n_randomized 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEP 5 | 52 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent |
| S-LITE | 52 | per_protocol | percent change in body weight from randomization after the diet to end of treatment | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2016 | age 18 to 65; BMI 32 to 43; no diabetes; at least 5 percent loss on 8 week low calorie diet |
| BARI-STEP | 68 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2022 | age 18 to 65; at least 1 year after primary bypass or sleeve; less than 20 percent weight loss from surgery |
| NCT01272219 | 56 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2011 | age 18 or more; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes; prediabetes allowed |
| STEP 10 | 52 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Adults with obesity and prediabetes; diabetes excluded |
| NCT03038620 | 40 | completers | percent change in body weight from baseline | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2017 | age 35 or more; BMI 30 or more, or 27 or more with metabolic syndrome; no diabetes |
| SURMOUNT-CN | 78 | completers | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Chinese adults; BMI 28 or more, or 24 or more with a weight related comorbidity; no diabetes |
| NCT00781937 | 56 | full_analysis | percent change in fasting weight from randomization | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2008 | BMI 30 or more or 27 with comorbidity; no diabetes; at least 5 percent loss on run in |
| STEP7 | 44 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 or older; BMI 30 or more, or 27 or more with a weight related comorbidity including T2D |
| STABLE Wt Loss | 60 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c 6.5 percent or less |
| OASIS 1 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | overweight or obesity |
| STEP 8 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or higher, or 27 with a weight related comorbidity; no type 2 diabetes |
| STRIVE | 52 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2017 | age 18 to 75; BMI 35 or more plus prediabetes, T2D, hypertension or sleep apnea; no insulin or GLP-1 RA |
| STEP 6 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | |
| NCT02453711 | 52 | full_analysis | percent change in body weight | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2015 | BMI 30 or more without diabetes |
| S003017 | 52.14 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 20 to 65; BMI above 35; 12 to 36 months after bariatric surgery with suboptimal stable weight loss or regain |
| S003032 | 52.14 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | age 18 to 65; BMI 27 or higher; scheduled for intragastric balloon |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| STEP 5 | A1 | SEMA_SC_2p4MG_QW | 52 | arm, percent_change | -15.800 | 0.762 | 149 | registry:outcomes | |
| STEP 5 | A2 | PLACEBO | 52 | arm, percent_change | -3.300 | 0.563 | 129 | registry:outcomes | |
| S-LITE | A1+A2 | PLACEBO | 52 | arm, percent_change | 4.180 | 1.116 | 65 | arms_combined | R0006966:Supplementary Table 2 |
| S-LITE | A3+A4 | LIRA_SC_3p0MG_QD | 52 | arm, percent_change | -4.140 | 1.087 | 65 | arms_combined | R0006966:Supplementary Table 2 |
| BARI-STEP | A1 | PLACEBO | 68 | arm, percent_change | 0.900 | 2.200 | 29 | R0014003:Results | |
| BARI-STEP | A2 | SEMA_SC_2p4MG_QW | 68 | arm, percent_change | -18.200 | 2.300 | 34 | R0014003:Results | |
| NCT01272219 | A1 | LIRA_SC_3p0MG_QD | 56 | arm, percent_change | -7.980 | 0.135 | 2,432 | registry:outcomes | |
| NCT01272219 | A2 | PLACEBO | 56 | arm, percent_change | -2.620 | 0.164 | 1,220 | registry:outcomes | |
| STEP 10 | A1 | SEMA_SC_2p4MG_QW | 52 | arm, percent_change | -14.400 | 0.696 | 129 | registry:outcomes | |
| STEP 10 | A2 | PLACEBO | 52 | arm, percent_change | -2.700 | 0.529 | 66 | registry:outcomes | |
| NCT03038620 | A1 | LIRA_SC_3p0MG_QD | 40 | arm, percent_change | -6.590 | 0.562 | 73 | registry:outcomes | |
| NCT03038620 | A2 | PLACEBO | 40 | arm, percent_change | -1.190 | 0.631 | 55 | registry:outcomes | |
| SURMOUNT-CN | A1 | TIRZ_SC_10MG_QW | 78 | arm, percent_change | -8.738 | 0.943 | 54 | R0007857:Supplement Table S2 | |
| SURMOUNT-CN | A2 | TIRZ_SC_15MG_QW | 78 | arm, percent_change | -10.567 | 1.462 | 49 | R0007857:Supplement Table S2 | |
| SURMOUNT-CN | A3 | PLACEBO | 78 | arm, percent_change | -2.472 | 1.126 | 39 | R0007857:Supplement Table S2 | |
| NCT00781937 | A1 | LIRA_SC_3p0MG_QD | 56 | arm, percent_change | -6.110 | 0.660 | 194 | registry:outcomes | |
| NCT00781937 | A2 | PLACEBO | 56 | arm, percent_change | -0.050 | 0.630 | 188 | registry:outcomes | |
| STEP7 | A1 | SEMA_SC_2p4MG_QW | 44 | arm, percent_change | -12.500 | 0.480 | 238 | registry:outcomes | |
| STEP7 | A2 | PLACEBO | 44 | arm, percent_change | -3.600 | 0.548 | 116 | registry:outcomes | |
| STABLE Wt Loss | A1 | SEMA_SC_2p4MG_QW | 60 | arm, percent_change | -15.100 | 1.300 | 72 | n_randomized | R0013679:Table 3 |
| STABLE Wt Loss | A2 | PLACEBO | 60 | arm, percent_change | -3.400 | 1.800 | 48 | n_randomized | R0013679:Table 3 |
| OASIS 1 | A1 | SEMA_PO_50MG_QD | 68 | arm, percent_change | -15.800 | 0.579 | 317 | registry:outcomes | |
| OASIS 1 | A2 | PLACEBO | 68 | arm, percent_change | -2.200 | 0.419 | 295 | registry:outcomes | |
| STEP 8 | A1 | SEMA_SC_2p4MG_QW | 68 | arm, percent_change | -16.400 | 0.971 | 117 | registry:outcomes | |
| STEP 8 | A2 | LIRA_SC_3p0MG_QD | 68 | arm, percent_change | -6.400 | 0.712 | 117 | registry:outcomes | |
| STEP 8 | A3 | PLACEBO | 68 | arm, percent_change | -1.600 | 0.974 | 78 | registry:outcomes | |
| STRIVE | A1 | STANDARD_CARE | 52 | arm, percent_change | -2.700 | 0.705 | 93 | R0020855:Table 2 | |
| STRIVE | A2 | LIRA_SC_3p0MG_QD | 52 | arm, percent_change | -8.100 | 0.508 | 201 | R0020855:Table 2 | |
| STEP 6 | A1 | SEMA_SC_1p7MG_QW | 68 | arm, percent_change | -9.900 | 0.788 | 98 | registry:outcomes | |
| STEP 6 | A2 | SEMA_SC_2p4MG_QW | 68 | arm, percent_change | -13.400 | 0.619 | 193 | registry:outcomes | |
| STEP 6 | A3 | PLACEBO | 68 | arm, percent_change | -1.900 | 0.590 | 100 | registry:outcomes | |
| NCT02453711 | A1 | SEMA_SC_0p05MG_QD | 52 | arm, percent_change | -5.990 | 0.850 | 92 | registry:outcomes | |
| NCT02453711 | A2 | SEMA_SC_0p1MG_QD | 52 | arm, percent_change | -8.620 | 0.840 | 96 | registry:outcomes | |
| NCT02453711 | A3 | SEMA_SC_0p2MG_QD | 52 | arm, percent_change | -11.600 | 0.850 | 94 | registry:outcomes | |
| NCT02453711 | A4+A6 | SEMA_SC_0p3MG_QD | 52 | arm, percent_change | -11.275 | 0.599 | 190 | arms_combined | registry:outcomes |
| NCT02453711 | A5+A7 | SEMA_SC_0p4MG_QD | 52 | arm, percent_change | -15.065 | 0.592 | 200 | arms_combined | registry:outcomes |
| NCT02453711 | A8 | LIRA_SC_3p0MG_QD | 52 | arm, percent_change | -7.760 | 0.850 | 96 | registry:outcomes | |
| NCT02453711 | A9 | PLACEBO | 52 | arm, percent_change | -2.290 | 0.740 | 123 | registry:outcomes | |
| S003017 | A1 | LIRA_SC_3p0MG_QD | 52.14 | arm, percent_change | -4.400 | 0.900 | 24 | n_randomized | R0016758:Results |
| S003017 | A2 | PLACEBO | 52.14 | arm, percent_change | 1.400 | 1.000 | 24 | n_randomized | R0016758:Results |
| S003032 | A1 | STANDARD_CARE | 52.14 | arm, percent_change | -13.470 | 0.461 | 20 | R0015729:Table 4 | |
| S003032 | A2 | SEMA_SC_1p0MG_QW | 52.14 | arm, percent_change | -28.210 | 0.472 | 20 | R0015729:Table 4 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.